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Abstract
Background: Whether Folic acid is a potential drug that may prevent the progression of colorectal carcinoma and
when to use are important healthy issues we focus on. Our study is to examine the effect of folic acid on the
development of the CRC and the optimal time folic acid should be provided in a mouse-ICR model induced by 1,
2-Dimethylhydrazine. Also, we investigated the gene expression profile of this model related to folic acid.
Method: Female ICR mouse (n = 130) were divided into 7 groups either with the treatment of 1, 2-
Dimethylhydrazine (20 mg/kg bodyweight) weekly or folic acid (8 mg/kg bodyweight) twice a week for 12 or 24
weeks. Using a 4 × 44 K Agilent whole genome oligo microarray assay, different gene expression among groups
(NS, DMH, FA2, FA3) were identified and selected genes were validated by real-time polymerase chain reaction.
Results: Animals with a supplementary of folic acid showed a significant decrease in the incidence, the maximum
diameter and multiplicity of adenocarcinomas (P < 0.05). Furthermore, there were fewer adenomas or
adenocarcinomas developed in the group of folic acid supplementation in pre-adenoma stage compared to group
of post-adenoma stage. Meanwhile, about 1070 genes that were changed by 1, 2-Dimethylhydrazine can be
reversed by folic acid and 172 differentially genes were identified between the groups of pre- and post- adenoma
stage using microarray gene expression analysis.
Conclusion: Our study demonstrated that folic acid supplementary was significantly associated with the decrease
risk of CRC. And the subgroup of providing folic acid without precancerous lesions was more effective than that
with precancerous lesions.
Introduction
It is known that colorectal cancer (CRC) is one of the
most common cancers especially in western countries,
referred to a multiple process, multiple factors with high
recurrence and high mortality [1]. Chemoprevention
methods for CRC have obtained increasing attention as
surgery and chemotherapy strategies perform little func-
tion once diagnosed to be tumor that invades the mus-
cularis propria. Also, the Non-steroidal anti-
inflammatory drugs (NSAIDs), such as COX-2
inhibitors, are not always successful, and may have some
harmful side-effects [2]. Generally, clinical trials require
at least 3-5 years follow up and a large number of
patients are difficult to control their lifestyles such as
smoking and wine intake which may affect the incidence
of cancer [3,4]. Therefore, we choose animal model
induced by chemistry drugs 1, 2-dimethylhydrazine
(DMH) to simulate the formation of CRC. As azoxy-
methane (AOM) or 1, 2-dimethylhydrazine (DMH)-
induced colon carcinogenesis in mice or rat have been
identified as a useful tool [5-9]. In the previous study,
we have successfully induced CRC in this model using
ICR mice [9].
Folic Acid (FA) is one kind of water-solubility vitamin,
which has been believed to be chemo-preventive agent
that can provide methy-group to DNA thus impact
DNA synthesis and DNA methylation [10].
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mutation, DNA strand break and the impairment of
DNA repair, which finally result in cancer formation
[11].
However, there are many conflicting data about
whether FA can inhibit or promote colorectal adenoma
(CRA) from clinical or preclinical studies. Epidemiologic
study shows that folic acid is significant associated with
lower risk and not related to the increased risk of color-
ectal cancer, supporting folic acid as a protective role
for colon mucosa [12,13], including several large pro-
spective studies in 99,523 participants in the American
Cancer Prevention Study II (CPS-II) Nutrition Cohort
[12] and in double-blind, randomized clinical trial
(RCT) conducted by 9 clinical centers incorporating
1091 participants for 3 years follow up [13]. However,
the Aspirin/Folate Polyp Prevention Trial demonstrated
that about 67% increased risk of advanced lesions with
high malignant potential, and an increased risk of having
multiple adenomas among the folic acid supplementa-
tion group by providing folic acid for 6 years at 1 mg/d
[14]. While other researches have reported that there is
no relation or positive association between folic acid
supplementation and the risk of colon adenoma [15].
Therefore, a systematic description from RCTs investi-
gating the relation between folic acid supplementation
and the risk of colorectal cancer was conducted by
many groups. One recent Meta-analysis data revealed
that folic acid supplementary for 3 years had no effect
on the adenoma recurrence while had an increased risk
of adenoma lesion for those who received folic acid over
3 years [16]. Another Meta-analysis divided the RCTs
into different groups including populations with a his-
tory of adenoma and with an-average risk populations.
They concluded that the evidence that folic acid was
effective in the chemoprevention of colorectal cancer
was not enough in both populations [17].
Further, many researchers consider that the role of folic
acid might be two-sided, that is to prevent in early phage
of adenoma formation and to promote in late stage
depending on the time of folic acid administration. Pre-
clinical studies have suggested that folic acid may only
protect against the development of CRC in normal
colon-rectum rather in mucosa with an Aberrant Crypt
Foci (ACF) status [18], which is the earliest pre-neoplas-
tic lesion that can be recognized based on the morphol-
ogy and pathology features [19,20], and the results were
consistent with an AOM induced rat model of CRC [21].
These experiments demonstrated that folic acid had dual
effects on the development of CRC depending on the
timing and dose of the intervention of folic acid [11]
However, the function that folic acid may perform to the
exiting adenomas in chemicals induced mouse model
and the possible mechanism is still un-established now.
In this study, we use ICR mice with 1, 2-Dimethylhy-
drazine (DMH) interfered models to analyze the impact
of folic acid on different timing courses during the pro-
cesses of CRC. We have previously demonstrated that 4
weeks old ICR mice given high dosage (8 mg/ml) folic
acid for 20 weeks have much more apparent effects to
prevent CRC incidence than low folic acid dosage (4
mg/kg bodyweight) group using DMH-induced mice
model [9]. Therefore, to investigate the role of folic acid
in the process of adenoma formation, we use the dose
of 8 mg/kg bodyweight. Meanwhile, we inferred that the
occurrence of adenoma may take place at the course of
12 weeks based on the performance of mice in pre-
viously study, so we designed the 12
th week as the divi-
sion of the prophase or advanced stage of CRC. The
study is expected to guide the clinical application of
folic acid and to identify the mechanism of folic acid in
a microarray gene expression profile.
Materials and methods
Ethics Statement
Our study had been approved by Animal Care and Use
Committee of Shanghai Jiao-Tong University School of
Medicine Ren-Ji Hospital, Shanghai, China (approval ID:
2007-036. All animal procedures were performed
according to guidelines developed by the China Council
on Animal Care and protocol approved by Shanghai
Jiao-Tong University School of Medicine Ren-Ji Hospi-
tal, Shanghai, China.
Chemicals
1, 2-Dimethylhydrazine (DMH) and Folic acid (FA,
F8758) were obtained from Sigma Chemical Co. (St.
Louis, MO, USA). The PH value of DMH is adjusted
with NaHCO3 to 6.5-7.0. DMH was dissolved with Nor-
mal saline and Folic Acid with drinking water.
Experimental animals
130 females, 4 weeks old ICR mice (weight, 18-20 g;
grade, specific pathogen-free (SPF)) were bought from
the Chinese Academy of Sciences (Shanghai, China).
The mice were raised at constant temperature of 22°C
w i t har e l a t i v eh u m i d i t yo f6 0 %a n d1 2 - h o u rl i g h t / d a r k
cycles; they were supplied a standard laboratory diet and
drinking water. These 130 mice were randomly divided
into 7 groups (Figure 1): NS group = 20 (Subcutaneous
injection of physiological saline); DMH1 group = 20
(Subcutaneous injection of DMH for 12 weeks); DMH
group = 20 (Subcutaneous injection of DMH for 24
weeks); Cfa (control Folic Acid) = 10 (only intragastric
administration of folic acid without DMH injection; FA1
= 20 (intragastric administration of folic acid with DMH
injection for early 12 weeks); FA2 = 20(intragastric
administration of folic acid with DMH injection for later
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acid with DMH injection for 24 weeks). DMH was given
subcutaneous injection once a week at the dosage of 20
mg/kg and folic acid was given by intragastric adminis-
tration twice a week. All mice were weighted once a
week. At the 12
th weeks after DMH injection, 10 of NS
and groups of DMH1, FA1 were killed and the condi-
tions of organs were recorded. The mass number and
size were assessed using a micrometer. Some fresh
colon and rectal tissues were maintained immediately in
liquid nitrogen, and others include liver or gastric tis-
s u e sw e r ef i x e di nf o r m a l i ns o l u t i o na n de m b e d d e di n
paraffin blocks for pathological analysis. At the end of
24
th weeks, all remaining mice were killed using the
same methods.
Histological Analysis
For pathology analysis, 4-μm thick sections of formalin-
fixed, paraffin-embedded tissues were prepared. After
hematoxylin and eosin staining, the sections of each
tumor were examined under a light microscope (Olym-
pus, Japan).
RNA extraction and Real-time polymerase chain reaction
labeling, hybridization, and analysis
Total RNAs from normal colonic mucosa of all groups
were got using TRIzol (Invitrogen, USA) according to
manufacturer’s instruction. RNA content and purity
were measured using Nanodrop ND-1000, and denatur-
ing gel electrophoresis was performed. Next, Reverse
transcription and quantification of gene expression was
performed according to the manufacture’si n t r o d u c t i o n
(Takara). We used 18s as an internal control in Real-
time PCR. Next, 3 samples of non-tumor colon of the
group of NS, DMH, FA2, FA3 were amplified and
labeled with the Agilent Quick Amp labeling kit and
hybridized using Agilent whole genome oligo microarray
(Agilent Technologies, Palo Alto, CA, USA) by using
Agilent SureHyb Hybridization Chambers. Then, the
processed slides were scanned with the Agilent DNA
microarray scanner according to the settings provided
by Agilent Technologies.
The microarray data sets were normalized by Agilent
GeneSpring GX software (version 11.0) using the Agi-
lent FE one-color scenario (mainly median normaliza-
tion). Differentially expressed genes were identified via
the fold-change (FC) and p values of the t-test. Differen-
tially expressed genes are identified to have an FC of ≥
1.5 and a p value of ≤ 0.05 between two groups. Func-
tional differences of the differentially expressed genes
was analyzed using the Gene Ontology (GO; http://
www.geneontology.gov/).
Statistical analysis
The results of the animal experiments and real-time
PCR were analyzed using SAS9 . 2s o f t w a r e( S A SI n s t i -
tute Inc. USA) with data presented in the forms of
means ± SD. Student’s t-test was used to compare
values between two independent groups. Differences
were considered to be significance when p < 0.05.
Figure 1 Groups of this study. NS group = Subcutaneous injection of physiological saline; DMH1 group = Subcutaneous injection of DMH for
12 weeks; DMH group = Subcutaneous injection of DMH for 24 weeks; cFA (control Folic Acid) = only intragastric administration of folic acid
without DMH injection; FA1 = intragastric administration of folic acid with DMH injection for early 12 weeks; FA2 = intragastric administration of
folic acid with DMH injection for later 12 weeks; FA3 = intragastric administration of folic acid with DMH injection for 24 weeks.
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Results of Animal Experiment
In the 12
th week, 2 of 20 mice in DMH group were dis-
covered average 2 × 3 mm adenoma, while there is
none in FA1 and NS groups. Thus, the 12
th week after
DMH treatment might be considered to be the pre-
stage that adenomas formed in DMH-induced model.
We have successfully induced CRC in the animal
model with injection DMH for 24 weeks, which were
identified as adenocarcinoma by histology analysis (Fig-
ure 2A, B). Figure 1 shows mainly results of the experi-
ment. We can see that the incidence of DMH-induced
group is 90%, much higher than any other groups such
as FA2, FA3, which are 63%, 45% respectively (Figure
2C). There is significant difference between groups of
FA3 and DMH but not between FA2 and DMH groups.
However, the multiplicity and the size of the maximum
masses in FA2 and FA3 groups are much smaller
Figure 2 Main results of the animal experiment after sacrificed at the 24 weeks. A. The morphology of normal colon in macroscopic
observation (Upper) and microscopy (HE stained) (Lower). Neither signs of injury nor tumor were found in NS group and cFA group. B. The
morphology of colon adenocacinoma in macroscopic observation (Upper) and microscopy (HE stained) (Lower). C. The incidences of DMH-
induced colorectal tumor in different groups. DMH group is 90%, which is much higher than any other groups such as FA2, FA3 which are 63%,
45% respectively. Meanwhile, there is none in NS and cFA group. D. Maximum diameter of tumor among the 5 groups (NS, cFA, DMH, FA1 and
FA2). E. Tumor number in mice among the above 5 groups. (a: P < 0.05, FA3 and FA2 compared to DMH group; b: P < 0.05, FA2 compared to
FA3 group)
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mm), indicating that folic acid may prevent the growth
of adenomas.
Although the incidence in FA2 is higher than FA3, no
significant difference was seen between them (63% vs
45%). However, the number and the maximum diameter
of the masses in FA3 group (2.11 ± 1.05, 2.11 ± 0.60
mm) showed a significant smaller than FA2 group (3.83
± 1.11, 4.92 ± 1.24 mm), P < 0.05 (Figure 2D and Figure
2E).
There is no tumor shaped and weight loss in Folic
Acid control group and the mice behavior normal, so
we conclude that folic acid is safe to normal colon.
Meanwhile, there was no significant difference in the
growth and development of mice among DMH and
FA2, FA3 groups but groups between NS and DMH.
Also, a macroscopic and microscopic examination of
their kidneys, stomachs, lungs, liver, and spleen showed
no obvious abnormalities (data not shown).
FA-mediated differential gene expression profile in
mouse colorectal carcinogenesis model induced by DMH
With the quality control step, all twelve colonic tissues
were analyzed as described in the Methods section. The
microarray analysis was conducted in the NS group (3
samples), DMH group (3 samples), FA2 group (3 sam-
ples) and FA3 group (3 samples). Then we compared
the gene expression levels between the samples of group
NS and DMH, FA3 and DMH, FA2 and FA3.
A homogenous expression profile among the samples
of each group was shown after the hierarchical cluster-
ing analysis. And when the Fold Change (FC) is set >
1.5 and the p value at ≤ 0.05, we found that the expres-
sion of 12395 genes was significantly altered in the
DMH group compared to those in the NS group (see
additional file 1). Together with the result of FA3 vs
DMH (see additional file 2), we found that 642 genes
down-regulated and 428 genes up-regulated in FA3
group compared to DMH, which may indicate that folic
acid can reverse the gene expression that changed by
DMH (see additional file 3). Most of these genes are
metabolic-related enzymes and regulators which may
perform cellular binding and enzymatic activity, involved
in the biological regulation and developmental process.
Other genes which are differentially expressed are clo-
sely to carcinogenesis such as cell cycle, cell invasion
and apoptosis. In table 1, the most changed genes com-
paring FA3 group and DMH group are listed, among
which are some oncogenes, for example, Oil (oncopro-
tein induced transcript 1), Tnfrsf11b (tumor necrosis
factor receptor superfamily, member 11b), Hmgn5
(high-mobility group nucleosome binding domain 5) are
down-regulated while tumor suppressors such as Hnf4a
(hepatic nuclear factor 4, alpha), Cdhr2 (cadherin-
related family member 2), Muc2 (mucin 2) are up-regu-
lated. From the results of the microarray analysis, we
selected 5 genes i.e., K-ras, c-MYC, DNMT1, Tpd52,
CDKN1b for PCR confirmation because they are already
considered as tumor-related genes. The primers for
these genes are shown in Table 2.
However, from the analysis of microarray there are only
172 differentially genes expressed between FA2 group
and FA3 group (see additional file 4). Consistent with
the animal experiment that FA2 group have increase
number and diameter of multiple masses, there are
some tumor suppressors down-regulated in FA2 group,
such as VDR (vitamin D receptor, FC = 0.30101), CDX2
(FC = 0.24596), and oncogenes up-regulated, i.e, FN1
(fibronectin 1, FC = 3.859909), TNFRSF12A (tumor
necrosis factor receptor superfamily, member12a, FC =
2.515130), NPM1(nucleophosmin1, FC = 1.557789) that
have been functional in the process of cell proliferation,
cell adhesion, cell differentiation and apoptosis(see table
3). It is the first study that different genes are identified
caused by the time that folic acid is provided either in
the pre- or post- carcinoma stage.
Using the GO and KEGG software, we analyzed our
microarray dataset (on the basis of the results shown in
additional file 3) to identify whether specific biological
pathways or functional gene groups were differentially
affected by the supplementary of folic acid (see addi-
tional file 5). We found that there are 63 signaling path-
ways including some tumor-related pathways such as
Mismatch repair, focal adhesion, cell cycle and mTOR
signaling pathway et al. (see additional file 6). Impor-
tantly, there are some key enzymes of metabolism path-
ways including fatty acid metabolism, oxidative
phosphorylation decreased in FA3 group compared with
DMH group, which may indicate that the decrease of
the ability of the metabolism is unfavorable to tumor
growth. And the most enriched pathways are shown in
table 4.
Discussion
In this analysis with a DMH-induced CRC model, we
concluded that the supplementation of folic acid can
decrease the risk of CRC and the subgroup of providing
folic acid without precancerous lesions was more effec-
tive than that with precancerous lesions. Significantly,
there was a reduction in the tumor mass diameter and
multiplicity in folate supplementation group. Moreover,
the study is consistent with many other studies either in
rodent models or clinical medical researches. Recently, a
study that investigated 2299 incidents and 5655 CRA in
Nurses’ Health Study and Health Professionals Follow-
Up Study showed that folic acid intake 12-16 y before
diagnosis was inversely associated with CRC and identi-
fied the latency that folic acid should be provided.
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acid was provided after diagnosis [22]. With the same
kind of chemical in a rat model of CRC, folate defi-
ciency was found to enhance the development of
neoplasia compared to the diets containing 8 mg/kg
folic acid [21] but the study had no related mechanisms.
However, some studies observed the opposite results. Le
Leu [23] believed that folate deficiency can decrease the
Table 1 List of the most differentially expressed genes whose changes due to DMH treatment could be reversed by
folic acid
Accession number Gene symbol Gene Description Fold change P value
Downregulated genes
NM_207634 Rps24 ribosomal protein S24 (Rps24), transcript variant 2 0.002356454 2.05154E-06
NM_012052 Rps3 ribosomal protein S3 (Rps3) 0.00933479 6.38113E-06
NM_033073 Krt7 keratin 7 0.024674534 0.001286211
NM_024478 Grpel1 GrpE-like 1, mitochondrial (Grpel1) 0.029123617 3.65271E-05
NM_024243 Fuca1 fucosidase, alpha-L- 1 0.031740456 0.000162318
NM_146050 Oit1 oncoprotein induced transcript 1 0.032247549 0.001799574
NM_013614 Odc1 ornithine decarboxylase, structural 1 0.032361 4.48641E-05
NM_025431 Llph LLP homolog, long-term synaptic facilitation (Aplysia) 0.036784284 1.18163E-06
NM_008764 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b 0.041187965 7.03729E-05
NM_009402 Pglyrp1 peptidoglycan recognition protein 1 0.041272749 0.009299333
NM_010106 Eef1a1 eukaryotic translation elongation factor 1 alpha 1 0.041438052 7.22246E-06
NM_001008700 Il4ra interleukin 4 receptor, alpha 0.043141894 0.000223171
NM_182930 Plekha6 pleckstrin homology domain containing, family A member 6 0.04544609 0.001545018
NM_011463 Spink4 serine peptidase inhibitor, Kazal type 4 0.045587012 0.000688366
NM_016710 Hmgn5 high-mobility group nucleosome binding domain 5 0.046928235 0.000333311
NM_016981 Slc9a1 solute carrier family 9 (sodium/hydrogen exchanger), member 1 0.052191789 5.29847E-05
NM_145533 Smox spermine oxidase (Smox), transcript variant 2 0.053274908 6.23127E-05
NM_008305 Hspg2 perlecan (heparan sulfate proteoglycan 2) 0.056450624 0.001205571
NM_172051 Tmcc3 transmembrane and coiled coil domains 3 0.058793481 0.001122075
NM_009768 Bsg basigin (Bsg), transcript variant 1 0.061259044 0.000407939
Upregulted genes
NM_009946 Cplx2 complexin 2 1109.786672 0.000155322
NM_001039493 Plekhm3 pleckstrin homology domain containing, family M, member 3 56.2494337 0.000450001
NM_024272 Ssbp2 single-stranded DNA binding protein 2 (Ssbp2), transcript variant 2 54.215495 2.06403E-05
NM_175013 Pgm5 phosphoglucomutase 5 47.38198278 1.84156E-05
NM_008222 Hccs holocytochrome c synthetase 39.34022581 0.000130923
NM_001033364 Cdhr2 cadherin-related family member 2 38.97741927 0.000749154
NM_023566 Muc2 mucin 2 30.63268666 0.02159023
NM_010418 Herc2 hect domain and RCC1 (CHC1)-like domain (RLD) 2 29.34751955 0.003432199
NM_008261 Hnf4a hepatic nuclear factor 4, alpha 28.66993377 0.000234502
NM_176850 Bptf bromodomain PHD finger transcription factor 26.66298996 0.000156324
Fold change and P values are the results comparing FA3 group and DMH group.
Table 2 Primer sequence for real-time pcr
Gene name Forward sequence Reverse sequence Product
length
Tpd52 tctaaagtaggaggagccaagc gctctctgtcatctgttctgga 117
DNMT1 caagaagaaaggcaaggtcaac cctggatgctctcaagtaggtc 212
c-Myc atttctatcaccagcaacagcag aacataggatggagagcagagc 137
K-RAS tggtcctggtagggaataagtg cccatctttgctcatcttttct 191
CDKN1b cttgcccgagttctactacagg agagtttgcctgagacccaat 127
Tnfrsf12a cgaccacacagcgacttct ccaaaaccaggaccagactaag 106
VDR tgaaggagttcatcctcacaga gataatgtgctgttgctcctca’ 128
18S rRNA cggacaggattgacagattgatagc tgccagagtctcgttcgttatcg 150
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Accession number Gene symbol Gene Description Fold change P value
Upregulated genes
NM_009758 BMPR1A bone morphogenetic protein receptor, type 1A 2.044809816 0.015778782
NM_008722 Npm1 nucleophosmin 1 1.557789177 0.019815969
NM_022563 Ddr2 discoidin domain receptor family, member 2 3.237694059 0.036468073
NM_026653 Rpa1 replication protein A1 1.568298305 0.049492698
NM_010730 ANXA1 annexin A1 3.666236872 0.034499347
NM_009242 SPARC secreted acidic cysteine rich glycoprotein 2.576417983 0.004456278
NM_025866 Cdca7 cell division cycle associated 7 2.483199204 0.032125313
NM_013749 TNFRSF12A tumor necrosis factor receptor superfamily, member 12a 2.515130632 0.001750863
NM_026148 LIMS1 LIM and senescent cell antigen-like domains 1 1.897061785 0.022103283
NM_010233 Fn1 fibronectin 1 3.859908549 0.036063689
NM_133918 EMILIN1 elastin microfibril interfacer 1 2.165900048 0.018411074
NM_133721 ITGA9 integrin alpha 9 2.471522431 0.019449109
NM_022563 DDR2 discoidin domain receptor family, member 2 3.237694059 0.036468073
NM_178665 LPP LIM domain containing preferred translocation partner in lipoma 4.202943318 0.034835063
NM_026361 PKP4 plakophilin 4 1.685566251 0.028039843
NM_010480 HSP90AA1 heat shock protein 90, alpha (cytosolic), class A member 1 1.656494408 0.029335434
NM_010135 ENAH enabled homolog (Drosophila) (Enah), transcript variant 1 2.96541359 0.030677412
NM_013885 CLIC4 chloride intracellular channel 4 1.737725253 0.044653582
NM_010663 KRT17 keratin 17 3.435610932 0.02165621
NM_001081185 Flnc filamin C, gamma 4.041058771 0.02814183
Downregulated genes
NM_007673 Cdx2 caudal type homeobox 2 0.24596643 0.030973362
NM_145953 CTH cystathionase 0.31273227 0.002366272
NM_008885 PMP22 peripheral myelin protein 22 0.576303226 0.031915491
NM_011146 Pparg peroxisome proliferator activated receptor gamma 0.483425898 0.035947091
NM_138942 Dbh dopamine beta hydroxylase 0.411709887 0.018408936
NM_020257 CLEC2I C-type lectin domain family 2, member i 0.572216631 0.009695318
NM_010708 LGALS9 lectin, galactose binding, soluble 9 0.610346325 0.033584593
NM_011146 PPARG peroxisome proliferator activated receptor gamma 0.483425898 0.035947091
NM_009504 VDR vitamin D receptor 0.30101348 0.021805069
NM_015789 DKKL1 dickkopf-like 1 0.628957018 0.004386895
Fold change and P values are the results comparing FA2 group and FA3 group.
Table 4 The most enrichment pathways related to tumorgegesis by KEGG
Pathway ID Pathway name Selection Count Count Enrichment
mmu05219 Bladder cancer - Mus musculus (mouse) 22 44 3.709033
mmu05216 Thyroid cancer - Mus musculus (mouse) 17 31 3.597993
mmu03430 Mismatch repair - Mus musculus (mouse) 13 23 3.030142
mmu05211 Renal cell carcinoma - Mus musculus (mouse) 30 77 2.524291
mmu04520 Adherens junction - Mus musculus (mouse) 29 79 2.035831
mmu04912 GnRH signaling pathway - Mus musculus (mouse) 36 104 1.939698
mmu05214 Glioma - Mus musculus (mouse) 27 74 1.892937
mmu04110 Cell cycle - Mus musculus (mouse) 46 140 1.872654
mmu05215 Prostate cancer - Mus musculus (mouse) 31 94 1.446692
mmu04150 mTOR signaling pathway - Mus musculus (mouse) 20 56 1.429803
mmu05200 Pathways in cancer - Mus musculus (mouse) 98 345 1.369825
mmu05221 Acute myeloid leukemia - Mus musculus (mouse) 21 61 1.309804
“SelectionCounts” stands for the Count of the DE genes’ entities directly associated with the listed PathwayID;
“Count” stands for the count of the chosen background population genes’ entities associated with the listed PathwayID;
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SD-rat model. To this point, we think that the animal
strain, experimental condition, experiment skills, folic
acid manufactories, folic acid intervention time et al
may contribute to these differences in varies studies.
Also, there is a possibility that excessive intake of folic
acid could have promoted the growth of pre-neoplastic
lesions so that our study support that enteroscope
should be conducted for the cases in clinical studies
before incorporated.
On the other hand, there are still no significant differ-
ences in the incidence of cancers between group FA2
and FA3 even though the maximum diameter and the
number of the tumor mass are significantly decreased in
FA3 group. It may be due to too small number of mice
or too much difference among individuals. In another
respect, not all the mice had adenomas in the 12
th week
as the incidence was only 10% among DMH1 group. So,
further study should extend the number of samples to
get more objective results.
Next, we use microarray gene expression profile analy-
sis to study the mechanism of folic acid-mediated pre-
vention of colon tumors and the difference in folic acid
intervention time. To our knowledge, this is the first
investigation to use microarray technology to study the
role of folic acid in the prevention of CRC and the dif-
ference of folic acid intervention times.
Firstly, when the FC was set to ≥ 1.5, 642 genes that
changed with the treatment of DMH could be reversed
with folic acid supplementary. We selected 5 known
tumor-related genes i.e., K-ras, c-MYC, DNMT1, Tpd52,
CDKN1b for PCR confirmation [Figure 3]. It is known
that genetic alterations may contribute substantially to
the pathogenesis of colon cancer. Point mutation of K-
ras (occurring in 40% of sporadic CRCs) is an estab-
lished predictor of absence of response to epidermal
growth factor receptor (EGFR) -targeted agents [24,25].
Hutchins [26] reported that KRAS mutant tumors were
more evenly distributed: 40% right colon, 28% left colon,
and 36% rectal tumors compared to BRAF mutant
tumors. Meanwhile, the relationship between Folic acid
and KRAS has been studied. Some suggested that the
effect of folate on rectal cancer risk is different to men
and women which may depend on the status of K-ras
mutation of tumors. They believed that folate intake was
related to a decreased risk of G > A transitions (RR-
Figure 3 Differentially expressed genes validated by real-time polymerase chain reaction (q-PCR).W eu s e d1 8 sr R N Aa sa ni n t e r n a l
control. Relative mRNA expression was calculated according to the 2
-ΔΔT method. Data are expressed as the mean ± SD of 10 samples. The
significance of the varieties between the average values of groups DMH and FA3 was analyzed through student’s t-t test. (*: P < 0.05, between
FA3 and DMH group)
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T and G > C transversions in tumors (RR = 2.69, 95%
CI = 1.43-5.09)[27].
CDKN1b (cyclin-dependent kinase inhibitor 1B, FC =
7.992979) which is also known as p27 encodes a protein
which belongs to the Cip/Kip family of cyclin dependent
kinase (Cdk) inhibitor proteins [28] It is often considered
as a cell cycle inhibitor protein because its major function
is to control the cell cycle progression at G1 phase so
that can prevent the development of cancer. Reduced
p27 levels were found in different cancerous stages in
hepatocelluar carcinomas [29]. Some studies demon-
strated that loss of p27 expression is associated with a
higher response rate to CRC chemo-therapy [30]. The
p27KIP1 null (-/-) mouse shows a significant increase in
cell proliferation, resulting in approximately 30% increase
in mass size, multiple organ hyperplasia [31]. Together,
these researches supported p27 as an important tumor
suppressor and suggest that events leading to p27 upre-
gulation may inhibit the tumor progression.
The methylation of genomic DNA in malignant cells
is catalyzed by DNA methytransferases(DNMT)which
include maintenance DNA methyltransferase (Dnmt1),
DNMT1, de novo DNA methyltransferases (Dnmt3a
and 3b), 3a/3b. DNA methylation is an important form
of epigenetic that can regulate some gene expression
such as c-Myc, CDKN2a, CDH1 and VDR et al [32-34].
We have seen that the expression of DNMT1 was
increased in FA3 compared to DMH, which is consis-
tent with the research that the folate - and methyl-defi-
cient diet alters components of the DNA methylation
via both transcriptional and posttranscriptional mechan-
isms in in livers of F344 rats [35]. Meanwhile, some
methylation-related genes that are functional in carcino-
genesis can also be regulated by folic acid in terms of
DNA methylation [36].
Tumor necrosis factor receptor superfamily, member
12a (Tnfrsf12a), also known as fn14 or TWEAK-R have
been implicated in a variety of pathological processes
including chronic inflammation and cancers [37]. And
fn14 expression is at a relative lower level in normal tis-
sues while much higher in cancer cells or tissues [38].
Kawashima [39] reported that IL-13 may damage the
mucosa of colon via the function of TWEAK and Fn14
pathway and Fn14 could aggravate intestinal inflamma-
tion in patients with UC. So the relation between fn14
and diseases might suggest fn14 and TWEAK are targets
for cancer therapy [37]. In our study, Tnfrsf12a’s expres-
sion is 2.5 fold changes higher in FA2 group than FA3,
which may be explained that the degree of colon muco-
sal damage in FA2 was much worse and was prone to
develop to cancers compared to FA3. In this aspect, the
high expression of fn14 may contribute to the growth of
masses in FA2 group.
Vitamin D Receptor gene (VDR) is involved in the
progress of cancers or chronic diseases [40]. Some
argued that the polymorphism of VDR and CDX2 was
not associated with increased risk of CRCs [41]. While
others suggested that significant associations with VDR
polymorphisms was found not in colorectal cancers but
much stronger in cancers of breast, prostate and renal
cell carcinomas [42]. And the association between VDR
polymorphisms and folic acid has not been reported yet.
In another respect, VDR is considered to be an epithelial
marker in the process of Epithelial to mesenchymal
transition (EMT) and thus might have a suppressive
function of invasion [43]. Therefore, the expression of
many tumor suppressors such as VDR was much lower
(FC = 0.3010) compared with group FA2 and FA3,
which was opposite to oncogenes.
However, there are some limitations of our study
should be mentioned. First, we ignored the usage of the
B Vitamins in the animal experiment, which is impor-
tant in the process of Folic acid’ transport and storage
in liver. Therefore, Folic acid supplements may some-
times include vitamin B12 supplements with simulta-
neous administration of vitamin B12 [22]. However,
some studies do not think there are any influences exit-
ing with or without vitamin B12 [44]. Others even
found that treatment with folic acid plus vitamin B(12)
was associated with increased cancer outcomes [45].
Thus, consideration should be given to the potential
value of providing with or without vitamin B12 in addi-
tion to the current mandatory folic acid
supplementation.
Second, since folic acid is important in many pro-
cesses of metabolism and might help to protect against
the cardiovascular, mental diseases, cancer and birth
defects [46]. However, we have no indicators to find
other adverse effects but to observe the injury of organs
in this study. Even though there are no abnormalities
discovered in other organs except colon and rectum, the
function of folic acid is needed to be further studied in
terms of being effective to therapy.
Finally, although some similarities do exist between
chemical rodent models of colon cancer and human
natural CRCs, several respects of differs may also exist
indeed. For example, the dose and duration of folic acid
supplementation used in our study may be different
from human studies. So, considering the safety of che-
moprevention in clinical application, the optimal
researches should be established in humans based on
these findings with an initial colonoscopy before
incorporated.
In summary, for the first time, our data suggest that
folic acid supplementary in pre-cancerous era is much
more protective than that in post-cancerous stage in a
DMH induced mouse model and identify differential
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groups of pre or post-adenoma induced by folic acid
using microarray gene expression profile. Not only to
the reason that floate supplementation facilitates the
progression of (pre)neoplastic lesions though providing
nucleotide precursors to the rapidly replicating trans-
formed cells, thus accelerating proliferation [11]. We
also clarified that in gene expression profile, certain
oncogenes that promote tumor growth, cell cycle, cell
invasion such as TNFRSF12A, fibronectin 1, Cdca7 are
high expressed in FA2 group compared to FA3 group
while tumor suppressors are down-regulated such as
VDR, CDX2, which may partly explain the result. How-
ever, the mechanism why folic acid provided in different
phages can change these genes’ expression remains to
be studied.
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